| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $886,309 ) |
| | 2024 | 2024 | OPHIREX, INC | 5643 PARADISE DR STE 2 | CORTE MADERA | CA | 94925-1815 | MARIN | USA | R01FD007839 | Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming | 002 | 2 | FDA | 9/20/2024 | $0 |
| | 2024 | 2024 | OPHIREX, INC | 5643 PARADISE DR STE 2 | CORTE MADERA | CA | 94925-1815 | MARIN | USA | R01FD007839 | Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming | 001 | 2 | FDA | 9/15/2024 | $886,309 |
| | 2024 | 2023 | OPHIREX, INC | 5643 PARADISE DR STE 2 | CORTE MADERA | CA | 94925-1815 | MARIN | USA | R01FD007839 | Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming | 000 | 1 | FDA | 4/30/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $894,459 ) |
| | 2023 | 2023 | OPHIREX, INC. | 5643 PARADISE DR #2 | CORTE MADERA | CA | 94925-1815 | MARIN | USA | R01FD007839 | Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming | 000 | 1 | FDA | 9/20/2023 | $894,459 |
| | 2023 | 2023 | OPHIREX, INC. | 5643 PARADISE DR #2 | CORTE MADERA | CA | 94925-1815 | MARIN | USA | R01FD007839 | Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming | 001 | 1 | FDA | 9/20/2023 | $0 |
|
|
